Immunologic data supporting immediate antiretroviral therapy in primary human immunodeficiency virus type 1 (HIV-1) infection are emerging; however, clinical benefit has not been demonstrated. The clinical and virologic course of 47 patients who were enrolled from September 1993 through June 1996 and who were not initially treated with potent therapy was compared with the course of 20 patients who immediately began therapy with zidovudine, lamivudine, and indinavir. Demographic and baseline laboratory data were comparable. During 78 weeks of follow-up, the early-treatment cohort showed a reduced frequency of opportunistic infections (5% vs. 21.3%; relative risk, 0.11; ), less frequent progression to P p .
for the initiation of aggressive antiretroviral therapy during primary HIV-1 infection [11] [12] [13] [14] [15] [16] . It remains unclear whether immediate antiretroviral therapy yields measurable clinical benefit.
Clinical studies of reverse-transcriptase (RT) inhibitors initiated during primary HIV-1 infection have shown modest effects on HIV-1 plasma load, increases in CD4 ϩ T cell counts, and less frequent oral candidiasis and varicella zoster reactivations [17] [18] [19] [20] [21] . Highly active antiretroviral therapy (HAART) regimens containing protease inhibitors (PIs) have demonstrated profound suppression of plasma HIV-1 RNA levels and associated increases in CD4 ϩ T cell counts [22, 23] . During chronic HIV-1 infection, combination antiretroviral regimens containing a PI have demonstrated clinical benefit in morbidity and mortality [24] [25] [26] [27] . However, applicability of these data to justify the initiation of antiretroviral therapy during primary HIV-1 infection may be confounded by the high level of HIV-1 replication during this time and the related potential for mutations that confer resistance, the potential lack of clinical benefits in persons not yet manifesting AIDS-associated conditions, and the potential long-term toxicity of combination regimens in persons who will theoretically require lifelong treatment. Despite these concerns, there is widespread advocacy for early intervention [11] [12] [13] [14] [15] .
Since the establishment of a clinic devoted to acute HIV-1 infection in 1993, uniform enrollment and follow-up procedures for patients with clinical, serologic, and virologic evidence of acute HIV-1 infection have been followed [7, [28] [29] [30] [31] . The present study compares the clinical and virologic outcome of 67 consecutively enrolled patients who did or did not initiate combination antiretroviral treatment within the first 90 days of HIV-1 infection.
Patients and Methods
Study population. To evaluate the effects of immediate therapy on clinical outcome, we compared the virologic and clinical course of patients with primary HIV-1 infection who were seen within 90 days of onset of acute retroviral illness or within 90 days of a documented acute asymptomatic HIV-1 seroconversion [28] [29] [30] [31] . The control cohort for this study consisted of 47 patients who were seen within 90 days of infection (onset of symptoms of seroconversion, evolving Western blot, or recent ELISA seroconversion) from September 1993 through June 1996. During these years, therapy was not initiated at enrollment; antiretrovirals were initiated only later in the course of infection, according to treatment guidelines based on CD4
ϩ T cell count, clinical course, and, subsequently, plasma HIV-1 RNA levels (see below) [27, 32] . This cohort of patients is referred to as the delayed-treatment cohort.
In 1996, when the benefit of combination therapy with indinavir was demonstrated, we initiated an investigation to evaluate the effects of indinavir (800 mg 3 times daily), zidovudine (200 mg 3 times daily and then 300 mg twice daily as this became available), and lamivudine (150 mg twice daily) on the clinical and virologic course of early HIV-1 infection [23] [24] [25] [26] . The purpose of limiting therapy to those seen within the initial 90 days after infection was to evaluate whether eradication of HIV-1 from lymphoid reservoirs was possible with the initiation of potent antiretrovirals early in the course of disease. From July 1996 through June 1998, 23 patients with acute HIV-1 infection were enrolled. Of these 23 patients, 20 accepted therapy and were included in the study, 2 declined therapy, and 1 was excluded from indinavir therapy because of a history of renal calculi.
An intent-to-treat analysis was used, in which all delayed-treatment patients were considered to be untreated for the entire 78-week period, even if antiretroviral therapy was used later. Of the 47 delayed-treatment patients seen from 1993 through 1996, 40 received no antiretroviral therapy during the 78-week follow-up, 7 initiated stavudine or zidovudine monotherapy within 6 months after enrollment (mean, 105 days; range 41-154 days), 2 initiated therapy with 2 nucleoside RT inhibitors 26 and 52 weeks after enrollment, respectively, and 2 began combination regimens containing PIs 52 weeks after HIV-1 infection. Thus, our analysis largely compares a HAART with an untreated group; however, since 11 patients in the delayed-treatment group initiated some antiretroviral therapy during follow-up, our analysis, especially after week 52, is conservative and somewhat weighted against demonstrating the benefit of early therapy.
Patients underwent a standardized medical history and physical examination at enrollment. Follow-up included biweekly visits for 2 months, monthly visits during the remainder of the first year, and quarterly visits thereafter. Patients receiving a combination of antiretrovirals had additional visits at weeks 1 and 3. Standardized casereport forms were used at each study visit, and samples were obtained for virologic and immunologic assays at standardized time points, as described elsewhere [28] [29] [30] [31] . Toxicities to medications were graded according to the Division of AIDS, National Institute of Allergy and Infectious Diseases, toxicity scale [33] . Standardized drug modifications were stipulated in the treatment protocols. Substitution of stavudine was permitted for zidovudine intolerance. Dose adjustments were not permitted for zidovudine, lamivudine, or indinavir. Centers for Disease Control and Prevention (CDC)-defined opportunistic infections and other mucocutaneous and respiratory conditions were confirmed by medical evaluation at a study visit or by patients' primary care providers [34] . Between 9 and 12 months, all patients were asked to undergo excisional lymph node biopsy; 7 initially untreated and 5 treated patients consented.
Laboratory methods. The diagnosis of acute HIV-1 was made by previously defined criteria. In brief, patients had a documented test result negative for HIV-1 or compatible acute retroviral syndrome and confirmed seroconversion to HIV-1 [22, [28] [29] [30] [31] . HIV-1 isolation, quantitative microculture, syncytia formation (MT-2 assay), and plasma HIV-1 RNA assays were performed, as described elsewhere [28] [29] [30] [31] . Plasma HIV-1 RNA was assayed by use of a branched-chain DNA assay (Chiron Diagnostics), which has a lower limit of detection of 500 HIV-1 RNA copies/mL [35] . In addition, all samples with !1000 HIV-1 RNA copies/mL subsequently were assayed in the Roche Diagnostic Systems ultrasensitive RT-polymerase chain reaction (RT-PCR) assay, which has a lower limit of detection of 50 HIV-1 RNA copies/mL of plasma [36] . Total HIV-1 DNA was determined in CD4 ϩ T cells by use of a quantitative-competitive PCR EIA method [37] . This assay measures both integrated and unintegrated viral DNA, as well as linear and circular forms of viral DNA, and relies on the coamplification of an internal quantitation standard. Phenotypic and genotypic analyses for resistance mutations were conducted at the Henry Ford Health Center (Detroit), using methods described elsewhere [38] [39] [40] .
Quantitation of HIV-1 in lymphoid tissue. We purified lymph node mononuclear cells (LNMC) from excisional biopsies and extracted (QIAmp; Qiagen) HIV-1 RNA, according to standard procedures. The RNA extracts were treated with 100 ng of DNase (Gibco) and then were reverse-transcribed in a solution containing 3 mM MgC1 2 , 10 mM dithiothreitol, 50 mM Tris-HC1 (pH 8.3), 75 mM KC1, 0.5 mM each dNTP, 0.4 mM specific antisense primer (below), 200 U of Moloney murine leukemia virus RT (Gibco BRL), 40 U of RNA guard (Pharmacia), and 10 mL (∼1 mg) of RNA in a 25-mL reaction. The resultant cDNA (500 ng/PCR reaction) was amplified by PCR and was probed for HIV-1 gag sequences, using a liquid hybridization procedure [41, 42] . This assay can detect 1-5 copies of HIV-1 RNA per microgram of total RNA.
PCR in situ hybridization for localization of HIV-1 DNA in tissue sections. Preparation of lymph node sections, reagents, thermocycling, and hybridization conditions for PCR in situ hybridization were as described elsewhere [42] [43] [44] . The PCR product was detected by in situ hybridization, using a cocktail of 3 HIV-1 gag-specific oligonucleotides labeled with digoxigenin-11-dUTP (Boehringer Mannheim). All 3 oligonucleotide probes were in sense orientation and were internal to the PCR primer binding sequences (SK102, 5 -GAGACCATCAATGAGGAAGCTGCAGAATGGGAT; SK19, 5 -ATCCTGGGATTAAATAAAATAGTAAGAATGTATAGCC-CTAC; and SJB9I, 5 -CTGTTCCTGGTTTCCTTGGGAAATCT- CTGA). Computerized image analysis was used to determine the percentage of positively staining cells in 10 representative regions of the lymph node under 10ϫ power, as described elsewhere [2, 44] . Statistical methods. Descriptive statistics were used to summarize the data. Because the mean time from enrollment to therapy initiation was 12 days, time zero and 12 days after enrollment were defined as the therapy initiation dates for the treated and the delayed-treatment patients, respectively. To exclude conditions resulting from seroconversion-related immunosuppression [31] , we included opportunistic and other conditions only after day 21 of antiretroviral therapy administration. For each individual, laboratory data values were interpolated between measurements. Overall trends by early-and delayed-treatment groups were characterized as pointwise medians and means of interpolated individual trajectories, respectively. The Wilcoxon rank sum test was used for comparison between the 2 groups. Estimation of CD4 ϩ T cell slope over time used the mixed-effect model to account for the correlation of repeated measures within the same individual, in which the patient was the random effect [45] . All P values were calculated as 2-sided. All analyses were performed at the Fred Hutchinson Cancer Research Center (Seattle).
Results
As shown in table 1, the demographic, clinical, and virologic data at enrollment were similar for the 20 treated patients and 47 delayed-treatment patients. Treated patients were followed up for a median of 98 weeks (range, 6-167 weeks); delayed-treatment patients were followed up for a median of 149 weeks (range, 4-322 weeks). Data for the first 78 weeks were included in this analysis, to allow for equal comparison between the treated and control groups. Genotypic analyses for resistance mutations were performed on the entry plasma isolates for all 20 treated patients and for 30 of 47 delayed-treatment patients. None of the 50 isolates tested had mutations associated with PI resistance. All isolates were wild type at position 184. One untreated patient had a mutation at codon 215 in the RT gene (T215F), and 2 treated patients had mutations K70R/T69N and T215D/M41L, which have been shown to confer reduced susceptibility to RT inhibitors. Both of the treated patients had rapid suppression of their plasma HIV-1 RNA levels, but the rates did not differ from those of the other treated patients (see below). Virologic response to antiretroviral therapy. At a median of 7 weeks (95% confidence interval [CI], [3] [4] [5] [6] [7] [8] , all 20 treated patients receiving HAART achieved plasma HIV-1 RNA levels !500 copies/mL; at a median of 19 weeks (95% CI, 12-20), they had achieved !50 copies/mL (figure 1A). Treated patients who continued to receive therapy maintained plasma HIV-1 RNA levels !50 copies/mL for the duration of follow-up. Three patients had transient (1 time point) increases in HIV-1 RNA !100 copies/mL at weeks 20, 32, and 44, respectively, after the initiation of therapy, with no apparent correlation with symptomatic intercurrent illnesses or vaccinations. Time to plasma HIV-1 RNA levels !50 copies/mL did not correlate with the time from onset of symptoms to the initiation of therapy, peak plasma HIV-1 RNA level, severity of seroconversion symptoms, or initial CD4
ϩ T cell count (data not shown). Delayed-treatment patients had a median HIV-1 RNA plasma level of copies/mL at baseline. At day 12 after en- 5 7.04 ϫ 10 rollment (defined as day zero for the comparison), the median plasma HIV-1 RNA level was copies/mL, which reflects 5 3.8 ϫ 10 the decrease in plasma viremia seen in very early HIV-1 infection, even without antiretroviral therapy. None of the delayed-treatment patients had plasma HIV-1 RNA levels !50 copies/mL during the 78 weeks. One patient began stavudine monotherapy 54 days after asymptomatic seroconversion and subsequently achieved plasma HIV-1 RNA levels !500 copies/mL. The virologic responses between treated and delayed-treatment patients became distinct after 6 weeks of therapy (figure 1A), and the difference was statistically significant for all time points thereafter ( ). At week 24, the median plasma HIV-1 RNA level for P ! .001 delayed-treatment patients was 35,124 copies/mL (range, 316-229,172 copies/mL), compared with !50 copies/mL for the patients treated with combination therapy.
Effect of therapy on proviral DNA and culturable virus in peripheral blood mononuclear cells (PBMC) and LNMC.
Other measures of HIV-1 replication also were suppressed by therapy, albeit not as completely as plasma HIV-1 RNA. HIV-1 DNA in PBMC decreased among delayed-treatment patients, from a median of copies/10 6 CD4 ϩ T cells at enrollment ; figure 1C) . P ! .01 Of the 20 treated patients approached for excisional inguinal 
Effect of combination antiretroviral therapy on CD4
ϩ T cells. Using a mixed-effects model to evaluate the trends in CD4 ϩ T cell counts over the 78 weeks of follow-up, we observed a sustained increase of 12.5 cells/mL per month in treated patients, compared with a loss of 9.5 cells/mL per month in delayed-treatment patients ( ; figure 3) . At week 78, the P ! .001 median increase in CD4 ϩ T cell counts for treated patients was 195 cells/mL (absolute value, 845 cells/mL) over baseline. The rate of increase in CD4 ϩ T cell count correlated with neither patient age nor time to plasma HIV-1 RNA suppression of !50 copies/L. At week 78, the median absolute CD4 ϩ T cell count among delayed-treatment patients was 457 cells/mL, which was 178 cells/mL lower than values at enrollment.
Progression to AIDS: frequency of opportunistic and nonopportunistic disease during follow-up.
Delayed-treatment patients had significantly more opportunistic and nonopportunistic diseases, and a higher proportion had rapid progression to AIDS (table 2; figure 4 ). During the 78 weeks of follow-up, 10 (21%) of 47 delayed-treatment patients experienced 20 discrete episodes of opportunistic infections versus 1 patient (who had discontinued therapy after 4 weeks) in the immediate, combination therapy group ( ). Among the delayed-treat-P p .02 ment cohort, 12 oral or esophageal candidal infections and 8 cases of oral hairy leukoplakia were documented (table 2). Six (13%) of 47 delayed-treatment patients developed CD4
ϩ T cell counts р200 cells/mL within 78 weeks of follow-up, including 1 patient who developed a sustained CD4 ϩ T cell count !200 cells/mL within 12 weeks of HIV-1 infection. Four of these 6 delayed-treatment therapy patients developed CD4
ϩ T cell counts р200 cells/mL before any definable opportunistic infection. None of the initially treated patients developed a CD4 ϩ T cell count р200 cells/mL during the initial 78 weeks of followup. Overall, 14 (30%) of the 47 initially untreated patients developed a class B or C opportunistic infection or CDC-defined AIDS during follow-up, compared with 1 (5%) of 20 in the immediate therapy group ( ; figure 4) . P p .01 A marked difference in the incidence of nonopportunistic conditions was noted in these 2 cohorts (table 3) . Nineteen (40%) of the 47 delayed-treatment patients had bacterial pneumonia, bronchitis, or sinusitis during follow-up; 39 discrete respiratory infections were documented. Of 20 of the treated patients, 3 (15%) experienced 5 episodes of respiratory infections (relative risk [RR], 0.27;
). Similar findings were seen P p .009 with mucocutaneous conditions: treated patients experienced significantly fewer new diagnoses of genital or rectal warts, folliculitis, psoriasis, seborrheic dermatitis, and severe gingivitis (RR, 0.17;
; table 3). Although both varicella zoster P ! .001 and herpes simplex virus reactivations also were reduced in the early-versus delayed-treatment cohorts, these differences did not reach statistical significance.
Adverse events and adherence to medications. Minor adverse events attributable to antiretroviral therapy were seen in all treated patients (figure 5). All patients reported some degree of nausea within the first 2 weeks of therapy. Seven patients (35%) reported moderate nausea and vomiting that required a change from zidovudine to stavudine, and 2 patients (10%) were changed from zidovudine to stavudine therapy because of anemia. One patient discontinued indinavir because of recurrent nephrolithiasis at week 16. Periungual abnormalities of the great toe developed in 2 patients, one of whom required surgical intervention. Severe aminotransferase abnormalities were seen in 2 patients. One patient developed cervicodorsal fat deposition ("buffalo hump") 21 months after therapy initiation.
Adherence to the treatment regimen was monitored by pill counts and daily diaries. A mean 96% (range, 76%-100%) of doses were taken by patients. Four patients reported 100% adherence. Treatment was discontinued during the first year in 4 patients. One of the patients discontinued combination therapy after 4 weeks for nausea and fatigue; he developed oral candidiasis 3 weeks later. The second patient discontinued therapy at 52 weeks, and within 12 weeks, his plasma HIV-1 RNA level increased to 684 copies/mL, at which point he established a plateau for the next 12 months. He has remained well but has begun to experience a reduction in his CD4 ϩ T cell count. Two additional patients discontinued therapy for personal reasons: one moved from the area and elected not to continue the treatment protocol, and the other was admitted to an in-patient substance-abuse rehabilitation center. Thus, although only 9 (45%) patients continued to follow the initial regimen, 16 (80%) were able to continue a 3-drug regimen that included a PI for the 78 week follow-up.
Discussion
Initiation of combination antiretroviral therapy at the time of diagnosis of primary HIV-1 infection produced significant virologic, immunologic, and clinical benefit in this cohort of patients with symptomatic primary HIV-1 infection. A treatment regimen consisting of 2 RT inhibitors and a PI resulted in prompt reductions in plasma HIV-1 RNA, 90% less frequent opportunistic infections (oral and esophageal candidiasis and oral hairy leukoplakia), and 70%-80% reduced frequency of respiratory and mucocutaneous conditions. More important, immediate treatment with combination antiretrovirals was protective against rapid progression to CDC Class B or C opportunistic infections or AIDS (defined by CD4 ϩ T cell counts р200 cells/mL). However, as demonstrated by a variety of techniques, initiation of therapy during primary infection did not prevent the establishment of viral latency or eradicate HIV-1 replication in any of the patients studied [46] [47] [48] [49] .
This study also provides information on a number of questions raised about the initiation of therapy during acute HIV-1 infection. Early concerns about the use of antiretroviral therapy during acute HIV-1 infection questioned whether prompt responses could be achieved if therapy were initiated during a period of high viremia and whether initiation of therapy at this stage would result in the rapid emergence of viral resistance and subsequent virologic breakthrough. All the initially treated patients reported here, even those with plasma HIV-1 RNA levels 1500,000 copies/mL at enrollment, achieved prompt and sustained virologic responses. One contributing factor to this prompt reduction in plasma viremia may have been the low frequency of drug resistance among the initially treated patients in the Seattle cohort. However, despite this susceptibility to antiretrovirals, eradication of HIV-1 from reservoirs in LNMC and PBMC was not achieved [6, [48] [49] [50] [51] . Similar to the finding of Zhang et al. [46] , sequencing of viral DNA from lymph node monocyte/macrophage and resting cell reservoirs in our patients after the initiation of HAART during primary HIV-1 infection has not revealed the emergence of RT or PI resistance muta- tions. Thus, although additional studies need to be performed, this study demonstrates that excellent antiviral responses can be achieved with early combination antiretroviral therapy. Although plasma HIV-1 RNA levels were sustained below the limit of detection among patients who continued to receive combination therapy, levels of total HIV-1 DNA in CD4 ϩ T cells and lymph node reservoirs were maintained, and low-level transcription of HIV-1 RNA in lymph node tissue could still be detected, even when therapy was initiated within days of the onset of seroconversion symptoms [6] . Perhaps the best in vivo demonstration of HIV-1 persistence, despite early initiation of therapy, was the increase in HIV-1 RNA and subsequent disease progression seen in both patients who elected to discontinue therapy but who continued to be followed up. The patient who discontinued therapy at 4 weeks developed oral candidiasis within 3 weeks, and the other patient subsequently had a CD4 ϩ T cell count decline. Thus, at present, it appears prudent to continue antiretroviral therapy among patients with primary HIV-1 infection who have undetectable plasma HIV-1 RNA levels, particularly as sustained increases in their CD4 ϩ T cell counts are observed (figure 3). Whether intermittent treatment interruptions would prevent the type of CD4 ϩ T cell count declines that we saw with complete interruption is unclear [50, 51] .
Although clinical benefits from early therapy were demonstrated, these benefits were accompanied by nearly universal drug-associated toxicities, which illustrates the importance of developing less toxic therapy [52] [53] [54] [55] [56] . Although frequent regimen alterations were needed, it was possible to keep 80% of patients on potent aggressive antiretroviral regimens for the duration of the study. Long-term studies of the patients are ongoing. As reported in other populations, fasting lipid abnormalities appear to be increasing in these patients [54] [55] [56] .
Balancing these side effects of therapy are the clinical benefits seen in initially treated patients. Patients who continued therapy with combination antiretrovirals experienced no opportunistic infections or CDC-defined AIDS after initiation of therapy, which is an improved and consistent finding versus the effects of zidovudine monotherapy during primary HIV-1 infection [20, 21] . Although selection bias must be considered in interpreting these results, the high incidence of progressive disease seen in those patients who received delayed treatment is characteristic of symptomatic seroconverters referred to HIV-1 care centers [57] [58] [59] .
An interesting clinical benefit observed in this cohort was a 70%-80% reduction in nonherpetic mucocutaneous and respiratory conditions seen during the early course of HIV-1 infection. These data suggest that in vitro immunosuppressive effects [8] [9] [10] seen with early HIV-1 infection appear to be operative in vivo; more detailed studies of the immunologic defects in HIV-infected persons may provide insight into the pathogenesis of psoriasis, seborrheic dermatitis, folliculitis, gingivitis, and other noninfectious complications of HIV-1 infection. These data also indicate that most early HIV-1 infections are not truly asymptomatic: 60% of the patients with HIV-1 infection in the Seattle cohort experienced infectious and immunologic complications within the first 78 weeks of HIV-1 infection.
Clinical outcomes from therapeutic interventions ideally are evaluated in randomized, blinded trials; however, the widespread belief that early therapy might prove advantageous precluded a randomized study [11] [12] [13] [14] . All available data indicate that at enrollment, the virologic, clinical, and demographic characteristics were similar in the early-treatment and delayedtreatment cohorts. Hence, the clinical and virologic benefits observed in the initially treated patients are likely attributable to antiretroviral therapy rather than to undefined host or virologic differences between the 2 cohorts. White men who have sex with men comprised a majority of study patients in both cohorts, which reflects the demographics of the HIV-1 epidemic in Seattle. As adherence and frequency of drug resistance play an important role in clinical outcome of HIV-1 infection, studies in other populations, such as women and injection drug users, are warranted.
In conclusion, initiation of potent antiretroviral therapy within 90 days of HIV-1 infection was associated with reduced HIV-1 in plasma and cellular compartments and with immune preservation, as evidenced by improved CD4 ϩ T cell counts, decreased opportunistic infections, and decreased frequency of respiratory and mucocutaneous conditions. Rapid progression to AIDS also was averted. Side effects of combination therapy were common, modifications to therapy frequent, and low levels of viral replication evident in cellular and anatomic reservoirs. With intensive counseling and close follow-up, most patients were maintained on a potent antiretroviral regimen containing a PI. Better-tolerated regimens with higher potency are still needed, as are long-term studies to determine whether clinical benefits are sustained.
